ArticleCureus2026
Dedifferentiated Carcinoma of the Ovary: A Rare Aggressive Subtype.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dedifferentiated carcinoma of the ovary (DDOC) is a rare and aggressive malignancy characterized by both differentiated and undifferentiated carcinoma components. While its endometrial counterpart, dedifferentiated carcinoma of the endometrium, is more frequent, DDOC remains poorly understood. We present the case of a young woman who presented with acute abdominal pain and was found to have a large complex ovarian mass. Histopathological examination revealed a combination of endometrioid carcinoma and undifferentiated carcinoma. Immunohistochemical analysis demonstrated distinct staining patterns, with the undifferentiated component exhibiting focal pan-cytokeratin positivity and loss of paired box gene 8 and estrogen receptor expression. The patient underwent standard paclitaxel-carboplatin chemotherapy but experienced rapid disease progression. DDOC poses significant diagnostic challenges due to its histological overlap with other high-grade ovarian malignancies. The presence of an undifferentiated component imparts a poor prognosis, even when it constitutes a minor portion of the tumor. Improved recognition, molecular characterization, and exploration of targeted therapies are essential for better clinical management of this rare and aggressive entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.